Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
To add new insight to our previous work on the molecular epidemiology of Bordetella pertussis in Argentina, the prn and ptxS1 gene sequences and pulsed-field gel electrophoresis (PFGE) profiles of 57 clinical isolates obtained during two periods, 1969 to 1989 and 1997 to 2006, were analyzed. Non-vaccine-type ptxS1A was detected in isolates obtained since 1969. From 1989 on, a shift of predominance from the vaccine prn1 type to the nonvaccine prn2 type was observed. This was also reflected in a transition of PFGE group IV to group VI. These results show that nonvaccine B. pertussis strains are currently circulating. To analyze whether the observed genomic divergences between vaccine strains and clinical isolates have functional implications, protection assays using the intranasal mouse challenge model were performed. For such experiments, the clinical isolate B. pertussis 106 was selected as representative of circulating bacteria, since it came from the major group of the PFGE dendrogram (PFGE group VI). Groups of mice were immunized either with diphtheria-tetanus-whole-cell pertussis vaccine (ptxS1B prn1) or a vaccine prepared by us containing B. pertussis 106. Immunized mice were then challenged with a B. pertussis vaccine strain (Tohama, harboring ptxS1B and prn1) or the clinical isolate B. pertussis 106 (ptxS1A prn2). An adequate bacterial-elimination rate was observed only when mice were immunized and challenged with the same kind of strain. For further characterization, comparative proteomic profiling of enriched membrane proteins was done using three vaccine strains and the selected B. pertussis 106 clinical isolate. By matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis, a total of 54 proteins were identified. This methodology allowed us to detect differing proteins among the four strains studied and, in particular, to distinguish the three vaccine strains from each other, as well as the vaccine strains from the clinical isolate. The differing proteins observed have cellular roles associated with amino acid and carbohydrate transport and metabolism. Some of them have been proposed as novel vaccine candidate proteins for other pathogens. Overall, the global strategy described here is presented as a good tool for the development of next-generation acellular vaccines.
Bottero
Daniela
D
Instituto de Bioquímica y Biología Molecular, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115 (1900), La Plata, República Argentina.
Gaillard
María Emilia
ME
Fingermann
Matías
M
Weltman
Gabriela
G
Fernández
Julieta
J
Sisti
Federico
F
Graieb
Augusto
A
Roberts
Roy
R
Rico
Osvaldo
O
Ríos
Gustavo
G
Regueira
Mabel
M
Binsztein
Norma
N
Hozbor
Daniela
D
D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D001118:Argentina; D001425:Bacterial Outer Membrane Proteins / Q000032:analysis* / Q000235:genetics; D001426:Bacterial Proteins / Q000032:analysis*; D001886:Bordetella pertussis / Q000737:chemistry* / Q000145:classification / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification; D015169:Colony Count, Microbial; D016521:Electrophoresis, Gel, Pulsed-Field; D005260:Female; D005838:Genotype; D006801:Humans; D007115:Immunization Schedule; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D037342:Pertussis Toxin / Q000032:analysis* / Q000235:genetics; D010567:Pertussis Vaccine / Q000276:immunology; D011110:Polymorphism, Genetic; D040901:Proteomics; D010566:Virulence Factors, Bordetella / Q000032:analysis* / Q000235:genetics; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control
D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; C083388:pertussis toxin, S1 subunit; C068929:pertactin; D037342:Pertussis Toxin
Infect Immun. 1999 Jun;67(6):3133-4
10338531
J Clin Microbiol. 2004 Jul;42(7):2890-7
15243034
Res Microbiol. 1999 Jun;150(5):333-41
10422694
Nature. 1970 Aug 15;227(5259):680-5
5432063
J Infect Dis. 1971 Sep;124(3):277-88
4947187
Anal Biochem. 1976 May 7;72:248-54
942051
Curr Top Microbiol Immunol. 1990;150:65-85
2404690
Lancet. 1990 Aug 11;336(8711):325-9
1697396
Mol Microbiol. 1991 May;5(5):1251-63
1659649
J Clin Microbiol. 1993 Oct;31(10):2745-50
8253976
Lancet. 1996 Jul 27;348(9022):271-2
8684225
Commun Dis Intell. 1997 May 29;21(11):145-8
9188218
Emerg Infect Dis. 1997 Apr-Jun;3(2):175-8
9204299
Infect Immun. 1998 Feb;66(2):670-5
9453625
J Infect Dis. 1999 Apr;179(4):915-23
10068587
Clin Infect Dis. 1999 Jun;28(6):1230-7
10451158
Microbiology. 1999 Aug;145 ( Pt 8):2069-75
10463173
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):227-36
15652812
Braz J Med Biol Res. 2005 May;38(5):777-81
15917960
J Clin Microbiol. 2005 Aug;43(8):3681-7
16081896
J Clin Virol. 2006 Feb;35(2):201-2
16230046
Infect Immun. 2006 Feb;74(2):931-9
16428737
Proteomics. 2006 Mar;6(6):1856-66
16456881
Vaccine. 2006 Apr 24;24(17):3513-21
16545509
J Clin Microbiol. 2006 Apr;44(4):1530-5
16597886
J Med Microbiol. 2006 Jul;55(Pt 7):943-6
16772423
Appl Environ Microbiol. 2006 Sep;72(9):6355-63
16957262
Microbes Infect. 2006 Jul;8(8):2082-7
16828571
J Evol Biol. 2006 Nov;19(6):1931-8
17040390
Vaccine. 2007 May 30;25(22):4335-9
17229502
Vaccine. 1999 May 14;17(19):2366-76
10392618
Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):174-81
10795589
Emerg Infect Dis. 2000 Jul-Aug;6(4):348-57
10905967
J Clin Microbiol. 2000 Jul;38(7):2793-4
10979749
J Infect Dis. 2000 Nov;182(5):1402-8
11023463
Emerg Infect Dis. 2001;7(3 Suppl):526-8
11485646
Infect Immun. 2001 Sep;69(9):5520-8
11500425
Vaccine. 2001 Nov 12;20(3-4):299-303
11672891
Microbiology. 2001 Nov;147(Pt 11):2885-95
11700340
Emerg Infect Dis. 2002 Jan;8(1):44-9
11749747
J Clin Microbiol. 2002 Mar;40(3):811-6
11880398
Microbiology. 2002 Jul;148(Pt 7):2011-8
12101289
Lancet Infect Dis. 2002 Dec;2(12):744-50
12467690
Pediatr Infect Dis J. 2003 Jan;22(1):22-7
12544404
CMAJ. 2003 Feb 18;168(4):453-4
12591789
Int J Med Microbiol. 2003 Jun;293(2-3):145-52
12868651
J Microbiol Methods. 2003 Dec;55(3):651-66
14607408
JAMA. 2003 Dec 10;290(22):2968-75
14665658
Nat Rev Microbiol. 2004 May;2(5):379-90
15100691
Vaccine. 2004 Jun 2;22(17-18):2122-8
15149768